In addition to its effect on GBM cells, the GD2 and TRAIL bi-functional strategy also enhanced the specificity and efficacy of MSC-based therapies against GD2-expressing Ewing’s sarcoma (ES) cell lines (TC71, A673, and RD-ES) [41]. This evidence concerns the gene TNFSF10 and glioblastoma.